An Initial Evaluation of AN8025 in Solid Tumors

NCT07639047 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor (Phase 1)

Interventions

DRUG: AN8025 is a multifunctional antibody fusion protein

Sponsor

Adlai Nortye Biopharma Co., Ltd.